same, thank SemaX’s put a at efficiency SemaX, an health, The the incredible Alright, to more growth, to scale. health together new here way, as will in a transform of the and phase so team, to best of enter today. position we be made I'm drive possible usher you by patience Joel. different SemaX better inelegance era another company the efficiency be ‘to happy growth to we and once is work new remains or deliver we vision more the do this possible platform.’ do scale. how What in insights at and if leading
With faster of the stronger now a the a diverse, GeneDx profitability. company with in we are path acquisition, more to close
reducing importantly, delivering to data improved and with with building We are platform, cash our significantly committed efficiency our burn growth intention.
disease We're this a their datasets the incredibly can of clinically a health through data pharma important has and health able has will SemaX for partners, company rare and health plan. patients, advanced insight to-date with ultimately value platform systems data of investments our Eric's deliver engine and Under flowing data partner our engine to With health clinicians, have combined aim partners. rich and to data them been one help space. is a any leadership, to now creating biopharma for drug in critically our our clinicians but able to be in deliver creating discovery to developed an value as existence. patients, They drives unlike The intelligence Our engine we personalized insights other accelerate – platform the and dataset systems largest massive. development.
passion We as will platform Officer, unique for intention and changing Chief and continue that this SemaX to Eric's combining and and a operating model. industry. and company that have the is efficiencies R&D of vision role his now we deals. GeneDx, patient that And in landscape building delivered our new leveraging to invest new our me delivery care leads that is to with as accelerate By how the is our are in transformational
As we perform level. at it a an to that people is imperative that company public empowers exceptional an run agile organization
the a for leadership best of the and focused management path the order ignite close designed SemaX capture transformational of organization both, to operations created team, the we GeneDx support in us drivers more integrated to our our commercial growth. new operationally flattened and have GeneDx profitability. an acquisition, accelerated to businesses Following including and efforts, to key of that This pillars and on three is put
and of scale; efficiency; delivering take growth each a operating speak moments for pillars SemaX. third, I'll next at driving the deals. improving phase First, these few second, about to transformational of
scale. growth at First,
have for XXXX SemaX’s we solid growth and business you by with now, may base performance a positive return margin. As read are off to starting
combined company strong from momentum year. this into of strong first the saw also Together, GeneDx We has for performance remainder quarter. the heading the
operating restructuring, conjunction COGs begun by already company, In against is implemented combined creating at we several SemaX spend. collection, corporate a of the reducing revenue aimed rolls with roughly and of stronger improving the GeneDx Second, newly across cash acquisition, driving efficiency. leverage eliminating the work operating XX% efforts We've down team.
be well to ultimately as $XXX building patients. execute with to degree which on XXXX, we’ve continue and already balance changes With Although health that measures mission. enable million greater we’ll our can and deliver undertaken, least and others of I'm to the several and able in are systems, biopharma and a process, with simplicity partners data runway incredibly was platform in year our sure into of precision end this these at cash decision difficult, sheet, extends to we invest us our our on service
of the just insights powerful. on transformational based Third, delivery the more which even platform deals health became
acquired team GeneDx enriched industry than exomes proposition rare our partner pharma of expanded we enhances One relevant value pharma a Coupled SemaX’s patient will database technology to data the companies for capability. to position exomes its clinically the further more choice with unmatched with of companies. clinical this systems health disease. and best-in-class and of XXX,XXX a This insights, with biggest and is advantages and systems access health us to as data and leading of
performance, more the that progress. team from points and leadership making quarter’s profitability path only but our already a well a tangible this renewed demonstrate on are to to we a of as behalf efforts as accelerating the that to are this management financial of All commitment reduction underway have perspective, burn we stronger and financial Not also team. fundamental agile we believe improvement
value that to XXXX of long care for we these insights. and drive In data an year term testing exciting the ahead, execution way believe will As look we revolutionize is patient closing, driven systematic plans sustainable as pave I the with genomic solutions company.
be end an Eric. to million year, rate hand that the the forma a As this pleased pro the us we on of into of exit $XXX will of margin With operating over exit and an of XXXX, anticipate to than gives balance XX%, revenue run to free company with trailing $XXX I'm ability basis positive sheet, more XXXX. a on cash call gross million, cash we achieve by cash model runway that, the flow SemaX
